The Clinical Effect of Recombinant Human Granulocyte-Colony Stimulating Factor to the Leukopenia During Chemotherapy in the Patients with Gynecologic Malignancies.
- Author:
In Suk CHOI
;
Jung Mi SON
;
Hyun KIM
;
Gun Sang YOO
;
jun Mo AN
;
Won Gue KIM
;
Un Dong PARK
- Publication Type:Original Article
- Keywords:
rhG-CSF;
chemotherapy;
gynecologic malignancy;
myelosuppression
- MeSH:
Drug Therapy*;
Hemorrhage;
Humans*;
Leukocyte Count;
Leukocytes;
Leukopenia*
- From:Korean Journal of Gynecologic Oncology and Colposcopy
1996;7(2):100-109
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
An increase in the dose of chemotherapy enhances the response of many experimental and clinical cancers, but the extent of chemotherapy dose escalation and repeated use is often limited by myelosuppression. The side effects of chemotherapy including bleeding and infection due to myelosuppression have resulted in delayed therapy and a reduction in the therapeutic dose, therefore it is necessary to overcome myelosuppression especially leukopenia in patients with gynecologic malignancies who recieved chemotherapy. This study is undertaken to investigate the clinical effects of rhG-CSF(recombinant human Granulocyte-colony stimulating factor) in 29 patients with gynecologic malignancy who recieved chemotherapy. It was given at a dose of 100 microgram bid/day subcutaneously until significantly increase of leukocyte count in leukopenic patient. The results showed, the rhG-CSF has significantly increased the number and function of leukocyte. The use of rhG-CSF was effective and useful to treat chemotherapy induced leukopenia and to accelerate the recovery from this complications.
